In the 1980s, our founding scientists made an unexpected observation.
The salivary glands, well-understood for their digestive functions, secreted factors with potent anti-inflammatory effects.
In 2011, AIM Therapeutics is poised to enter clinical development with a brand new therapeutic approach to multi-billion dollar global markets in asthma and chronic obstructive pulmonary disease [COPD].
AIM-102, our lead clinical drug candidate, is the first of a new class of non-steroidal, immune modulating anti-inflammatory drugs targeting these markets.
We intend to enter into development partnerships with the world’s leading drug developers to achieve our goal of delivering safer, more effective therapies to people dealing with chronic respiratory and inflammatory conditions.
Welcome to our site. We look forward to the opportunity to discuss our technology with you.Frank Gleeson
President & CEO
fgleeson@aimtherapeutics.com